CPC C12N 5/069 (2013.01) [A61B 17/1215 (2013.01); A61K 31/351 (2013.01); A61K 31/37 (2013.01); A61K 31/404 (2013.01); A61K 31/4706 (2013.01); A61K 31/496 (2013.01); A61K 31/5025 (2013.01); A61K 31/506 (2013.01); A61K 31/517 (2013.01); A61K 31/52 (2013.01); A61K 31/5377 (2013.01); A61K 31/55 (2013.01); A61K 38/10 (2013.01); A61P 9/00 (2018.01); A61P 9/10 (2018.01); C07K 14/495 (2013.01); C12N 2510/02 (2013.01)] | 16 Claims |
1. A method for treating a human subject at risk of suffering from an intracranial aneurysm comprising administering to said human subject a therapeutically effective dose of an autophagy inhibitor, wherein the autophagy inhibitor is selected from the group consisting of wortmannin, chloroquine, clomipramine, 3-Methyladenine, Bafilomycin A1, Pepstatin A, and Pepstatin E-64-d, wherein the human subject carries a variant affecting the expression of a Thrombospondin Type 1 Domain Containing 1 (THSD1) gene.
|